STUDY OBJECTIVE The U.S. Food and Drug Administration approval of the use of apixaban in patients with a creatinine clearance (CrCl) of < 15 ml/minute or in those receiving dialysis is based only on pharmacokinetic data as clinical trials of apixaban excluded patients with a CrCl of < 25 ml/minute or a serum creatinine concentration (SCr) of > 2.5 mg/dl. Thus, the objective of this study was to evaluate the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. DESIGN Retrospective, matched-cohort study. SETTING Community hospital. PATIENTS A total of 146 adults who received at least one dose of apixaban (73 patients) or warfarin (73 patients) while hospitalized between January 30, 2014, and December 31, 2015, and had a CrCl of < 25 ml/minute or SCr of > 2.5 mg/dl, or who received peritoneal dialysis or hemodialysis, were included. Patients who were taking warfarin and had a therapeutic international normalized ratio on admission were matched consecutively in a 1:1 fashion in chronologic order to patients taking apixaban based on renal function and indication for anticoagulation. MEASUREMENTS AND MAIN RESULTS The primary outcome was major bleeding. Secondary outcomes included the composite of bleeding (major bleeding, clinically relevant nonmajor bleeding, and minor bleeding) in addition to documented ischemic stroke or recurrent venous thromboembolism. A nonsignificant difference in the occurrence of major bleeding and composite bleeding was observed between patients who received apixaban compared with those who received warfarin (9.6% vs 17.8%, p=0.149, and 21.9% vs 27.4%, p=0.442, respectively). The occurrence of stroke was similar between the groups (7.5% in each group), and no recurrent venous thromboembolism events were noted in either group during the study period. CONCLUSION Apixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.
in Patients with Atrial Fibrillation (AVERROES) and Apixaban versus Warfarin in Patients with
Atrial Fibrillation (ARISTOTLE) clinical studies, which evaluated apixaban in patients with nonvalvular atrial fibrillation (NVAF), patients with severe renal insufficiency, defined as a creatinine clearance (CrCl) of < 25 ml/minute or a serum creatinine concentration (SCr) > 2.5 mg/dl, were excluded. 2, 3 The same exclusion criteria were also used for the study evaluating apixaban in the treatment of acute venous thromboembolism (VTE). 4 Patients with renal dysfunction inherently have a higher risk of bleeding than do those without renal dysfunction; thus, the safety of each anticoagulant should be evaluated in this patient population. 5 Apixaban has a distinctive dosing regimen. Rather than requiring dosage adjustment based on CrCl, apixaban is dose adjusted for patients with the indication of NVAF based on a combination of at least two of the following factors: SCr ≥ 1.5 mg/dl, age ≥ 80 years, or body weight ≤ 60 kg. 6 Patients with renal impairment, advancing age, or small body stature were considered to be at higher risk of bleeding in clinical trials. 7, 8 Therefore, the reduced oral dose of apixaban 2.5 mg twice/day was chosen because it demonstrated bleeding rates lower than enoxaparin in a phase 2 venous thromboembolism study. 7, 8 In January 2014, the U.S. Food and Drug Administration (FDA) updated the apixaban labeling with more explicit dosage recommendations for patients with renal impairment, including ESRD, and those receiving dialysis. 6 These patients should be prescribed standard doses based on indication unless they meet additional criteria for dosage adjustments.
Single-dose apixaban studies evaluating the effect of renal dysfunction on the drug's pharmacokinetics concluded that apixaban is well tolerated, and dosage adjustment based on renal function alone is not needed. 9, 10 However, patients with increasing severity of renal impairment were shown to have 16-44% higher apixaban exposure compared with patients with normal renal function. 9 After receiving a single dose of apixaban 5 mg immediately after a 4-hour dialysis session, patients with ESRD had 36% higher exposure than did those with normal renal function. 10 In a similar manner, a single-dose study evaluating the effect of chronic hemodialysis on rivaroxaban pharmacokinetics found that exposure to the drug increased by 56% when administered after dialysis. 11 Investigators concluded that these changes did not indicate a need for dosage adjustment as values were comparable to those in patients with moderate-to-severe renal dysfunction. It is important to note that none of these studies described the effect of renal dysfunction on multiple doses of apixaban or rivaroxaban over time once steady state is reached.
Currently, apixaban is the only oral anticoagulant, aside from warfarin, with FDA approval for use in patients with a CrCl < 15 ml/minute, as estimated by the Cockcroft-Gault equation, regardless of indication. 12 However, the approval of apixaban in this patient population was based solely on pharmacokinetic data and has yet to be clinically evaluated with respect to safety and effectiveness. Presently, to our knowledge, there are no published trials evaluating clinical outcomes of these dosing recommendations in this patient population. The purpose of this study was to evaluate the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment.
Methods

Study Design and Patient Cohorts
This single-center, retrospective, matchedcohort study evaluated patients at a 480-bed community hospital (Missouri Baptist Medical Center, St. Louis, MO) that consistently ranks as one of the best regional hospitals for cardiac care. Before data collection, this study was approved by the institutional review board. Informed consent was not necessary due to the retrospective nature of the study.
Patients aged 18 years or older who received at least one dose of apixaban or warfarin while admitted to the study institution between January 30, 2014, and December 31, 2015, were screened for inclusion. Patients with a CrCl < 25 ml/minute or a SCr > 2.5 mg/dl, or those receiving peritoneal dialysis or hemodialysis, were included to capture those patients excluded from previous clinical trials. 2, 3 Creatinine clearance was calculated with the Cockcroft-Gault equation using admission age and ideal body weight (actual weight was used for underweight patients) in addition to the most recent SCr value before initial dose administration as long as it was within the previous 24 hours. 12 Patients were excluded if an accurate assessment of dose or renal function could not be made (i.e., weight or SCr was missing). Patients receiving continuous renal replacement therapy were also excluded.
All patients who received at least one dose of apixaban during the study time frame were evaluated. Patients who received warfarin during this time period and had a therapeutic international normalized ratio (INR) on admission were consecutively and chronologically matched in a 1:1 fashion to those receiving apixaban based on renal function (Table 1 ) and primary indication for anticoagulation. Patients taking warfarin were assessed for time in therapeutic range for the duration of their hospital admission.
Study Outcomes
The primary outcome was major bleeding. Secondary outcomes were the composite of major bleeding, clinically relevant nonmajor bleeding, and minor bleeding in addition to ischemic stroke in patients with NVAF or recurrent VTE in patients treated for a pulmonary embolism or deep vein thrombosis, as defined by physician diagnosis obtained from the electronic medical record.
For the purpose of this study, major bleeding was defined according to modified International Society on Thrombosis and Haemostasis (ISTH) criteria as clinically overt bleeding accompanied by at least one of the following: a decrease in hemoglobin level of at least 2 g/dl, transfusion of at least 2 units of packed red blood cells, involvement of a critical site (intracranial, spinal, ocular, pericardial, articular, retroperitoneal, or intramuscular with compartment syndrome), resulting permanent disability, or fatal outcome. 13 A source of bleeding had to be documented in the electronic medical record in order to confirm bleeding and to prevent falsely elevated bleeding rates.
Clinically relevant nonmajor bleeding was defined as clinically overt bleeding that did not satisfy the criteria for major bleeding and led to hospital admission for bleeding, physicianguided medical or surgical treatment for bleeding, or a change in antithrombotic therapy due to bleeding. All clinically overt bleeding events not meeting criteria for major bleeding or clinically relevant nonmajor bleeding were classified as minor bleeding.
Patients were screened for bleeding and thromboembolic events from study inclusion until data collection was completed. Events were documented if the patient was readmitted to the study hospital or another hospital within the health care system or if in-hospital events were documented in the medical record.
Statistical Analysis
Baseline clinical and demographic characteristics, as well as primary and secondary outcomes, were analyzed by using the Student t test for continuous data and the v 2 or Fisher exact test for categorical data. A value of p<0.05 was considered to indicate a statistically significant difference. Analyses were performed by using IBM SPSS Statistics for Windows (IBM Corp. Armonk, NY).
Results
A total of 357 patients were screened for inclusion. All 73 patients evaluated for the apixaban arm were included. Of the 284 patients evaluated for the warfarin arm, 211 were excluded and 73 were included (Figure 1 On average, while admitted to the hospital, patients in the warfarin group received approximately 3.8 days of therapy compared with 4.3 days for patients receiving apixaban. Baseline characteristics were similar between groups, with no statistically significant differences noted (Table 2) . In each arm, 63% of patients had severe renal impairment, whereas 9.6% had ESRD and 27.4% were receiving dialysis. Collectively in both groups, 17 patients were admitted with acute kidney injury during their hospitalization without a documented history of chronic kidney disease.
14 Three patients in each group were included with a SCr > 2.5 mg/dl but a CrCl > 25 ml/minute. Creatinine clearances in these patients ranged from 26 to 36 ml/minute. In each arm, the majority of patients (72.6%) required anticoagulation for the primary indication of NVAF, whereas 26% required anticoagulation for VTE. One patient in each arm was using anticoagulation for thromboprophylaxis after orthopedic surgery. Of the patients receiving dialysis, 28 patients were anticoagulated for NVAF, 10 patients for VTE, and 2 patients for thromboprophylaxis. Although more patients in the apixaban arm were concomitantly taking antiplatelet medications, this difference was not statistically significant (p=0.66). Apixaban was a preadmission medication for 39 (53.4%) patients and was initiated in the hospital for the remaining 34 (46.6%) patients. Patients were primarily receiving the reduced dose of apixaban 2.5 mg twice/day (45 [61.6%] patients); however, apixaban 5 mg twice/day and 10 mg twice/day regimens were also ordered (27 [37%] patients and 1 [1.4%] patient, respectively). Of the 39 patients who were taking apixaban before admission, 7 (18%) patients were admitted taking an inappropriate dose, and the remaining 32 (82%) patients were admitted taking an appropriate dose. When apixaban was initiated in the hospital (34 patients), 26 (77%) patients were originally initiated on the appropriate dose. By discharge, 59 (80.8%) of the 73 patients in the apixaban arm were taking the appropriate dose based on indication. Most of the patients who were receiving the incorrect dose had the primary indication of VTE treatment and were inappropriately prescribed a reduced dose based on NVAF factors; this included patients who required anticoagulation for both VTE and NVAF. When patients treated for both VTE and NVAF were evaluated, the reduced dose was considered appropriate only if the patient had been anticoagulated for at least 6 months after the initial VTE event.
Warfarin was a preadmission medication in 100% of the 73 patients, as the inclusion criteria required the patient's INR to be therapeutic on admission. Throughout the index hospitalization, the average time in therapeutic range for patients receiving warfarin was 67.5%. The average/day dose of warfarin was 4 mg, which can be attributed to the elderly age (mean 79 yrs) of patients seen in the baseline demographics.
Overall, the occurrence of bleeding in this study ( Figure 2 ) was higher than that of the general population in previously published literature. 2, 3 This could be attributed to the high bleed risk, as the average HAS-BLED score was 3.4 and 3 in the apixaban and warfarin groups, respectively. 5 A lower proportion of patients in the apixaban arm (9.6% [7 patients]) experienced major bleeding compared with the warfarin arm (17.8% [13 patients]). However, one of the apixaban bleeding events was difficult to directly attribute to apixaban as the patient had also recently received rivaroxaban before being switched to apixaban for declining renal function. In addition, one of the warfarin bleeding events occurred in a patient with active gastric cancer and Helicobacter pylori infection, making a direct correlation with warfarin difficult. Of the major bleeding events, all seven patients in the apixaban group experienced a gastrointestinal bleed. The major bleeding sites for patients receiving warfarin were as follows: one retroperitoneal, one intraarticular, one intramuscular, and 10 gastrointestinal. Overall, the occurrence of composite bleeding was also higher in patients receiving warfarin, as 16 (21.9%) patients in the apixaban group had an episode of bleeding compared with 20 patients (27.4%) in the warfarin group. Although there was less major bleeding and composite bleeding in the apixaban arm versus the warfarin arm, these differences were not statistically significant (p=0.149 and p=0.442, respectively). Also, no statistically significant differences regarding antiplatelet use were noted between patients who experienced major bleeding and composite bleeding in either the apixaban arm (p>0.99 and p=0.859, respectively) or the warfarin arm (p=0.388 and p=0.262, respectively). Patients were screened for bleeding at a minimum of 5 months after discharge. There was a total of 26,944 patient-days of follow-up for patients receiving apixaban compared with 41,010 patient-days for patients receiving warfarin. This translates into 0.26 major bleeding event per 1000 patient-days compared with 0.317 event per 1000 patient-days for those receiving apixaban and warfarin, respectively. Of those patients who experienced a bleed, 12 patients in the warfarin group were readmitted Data are mean AE SD values or no. (%) of patients. ESRD = end-stage renal disease; LOS = length of stay; NVAF = nonvalvular atrial fibrillation; SCr = serum creatinine concentration; TIA = transient ischemic attack; VTE = venous thromboembolism; CHA 2 DS 2 -VASc = heart failure/reduced ejection fraction, hypertension, advanced age, diabetes, stroke/TIA, vascular disease, female sex (scoring system for estimating stroke risk); HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol (scoring system for estimating bleeding risk); MI = myocardial infarction; CAD = coronary artery disease. with a bleeding episode compared with 9 patients in the apixaban group. The occurrence of stroke was similar between groups, with four patients, of the 53, (7.5%) experiencing a stroke after the initiation of anticoagulation for NVAF in each treatment group (Figure 2) . Of the eight patients who experienced a stroke while receiving anticoagulation, one patient receiving warfarin had a subtherapeutic INR of 1.3, one patient had apixaban withheld for the creation of an arteriovenous fistula, and one patient was receiving an apixaban dose that was too low. The remaining five patients, two receiving apixaban and three receiving warfarin, were receiving the appropriate dose or had an INR within therapeutic range. These event rates of 2.7% in the apixaban group and 4.1% in the warfarin group were higher than reported in literature; however, it is important to note that these patients carried a high stroke risk (one patient had a CHA 2 DS 2 -VASc score of 6, three had a score of 7, and one had a score of 8). 3, 15 No patients being treated for VTE experienced a recurrent event during the study period.
When pooling together all patients included in the study, no statistically significant differences regarding major bleeding and composite bleeding were noted for patients receiving dialysis (p=0.663 and p=0.549, respectively). Major bleeding and composite bleeding rates were similar within the apixaban arm when comparing patients receiving dialysis with those not receiving dialysis (p>0.99). This was also true for patients in the warfarin arm, as no significant differences in major bleeding and composite bleeding rates were noted based on dialysis status (p=0.742 and p=0.384, respectively).
Discussion
Patients included in this study had a complicated clinical picture. In both groups, the mean CHA 2 DS 2 -VASc score was approximately 6, indicating that patients were at high risk for stroke, transient ischemic attack, and systemic embolism. 15 At the same time, patients had a mean HAS-BLED score of 3, indicating they were also at high risk for major bleeding. 5 Anticoagulation in this clinical scenario is a delicate balance, as the benefits of treatment must be weighed against the risks for each individual. This is the largest study, to our knowledge, evaluating clinical outcomes of apixaban in patients with ESRD or dialysis.
Management of medications in patients with renal impairment or those undergoing hemodialysis can be difficult, as many drugs are excreted by the kidneys into the urine. As kidney function declines, these drugs will potentially accumulate, leading to adverse events or toxicity. As many anticoagulants are excreted in the urine, Figure 2 . Occurrence of clinical outcomes in the patients receiving apixaban (n=73) and those receiving warfarin (n=73). The primary outcome was major bleeding. Secondary outcomes were the composite of major bleeding, clinically relevant non-major bleeding, and minor bleeding in addition to ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) or recurrent venous thromboembolism (VTE) in patients treated for a pulmonary embolism or deep vein thrombosis.
bleeding events in patients with renal impairment could increase if their dosages are not adjusted appropriately, including apixaban, which is 27% excreted by the kidneys. [6] [7] [8] A number of limitations exist within this study. As patients were only from a single-center, community hospital, the sample size was limited. Based on the major bleeding event rates and an a set at 0.05, this study had a 33% power to detect a significant difference. To achieve an 80% power to detect a difference, approximately 236 patients would need to be evaluated in each treatment group. Due to its retrospective nature, data extraction was dependent on the quality of documentation within the electronic health record. Physicians were able to make anticoagulation decisions independently, based on clinical judgment, which could introduce sampling bias. Patients who presented to the study center for the first time due to a bleeding event may not have been captured in the study if anticoagulation was not administered during the admission as the result of being withheld or discontinued. In addition, patients were not matched based on date of inclusion in the study, resulting in patients in the warfarin arm having a longer follow-up time. However, excluding patients in the warfarin arm without therapeutic INRs on admission could potentially mitigate this fact, as occurrence of bleeding is highest in the first few months after drug initiation. [16] [17] [18] Of the seven patients in the apixaban arm who experienced major bleeding, six had apixaban initiated during the index hospitalization. None of the patients in the warfarin arm began therapy during the study period compared with 34 patients (46.6%) in the apixaban arm who initiated therapy during this period. These factors could potentially cause underreporting of bleeding in the study population.
Conclusion
Although we found no statistically significant differences between the apixaban and warfarin groups regarding the occurrence of bleeding, stroke, or VTE in patients with severe renal dysfunction, similar or less bleeding was noted in patients receiving apixaban versus those receiving warfarin, suggesting that apixaban could potentially be safely used in this patient population with close monitoring. The results of this study also seem to reflect those in the subgroup analysis of the ARISTOTLE (Apixaban for Reduction In Stroke and Other ThromboemboLic Events in atrial fibrillation) trial. 3 In patients with severe or moderate renal impairment (CrCl ≤ 50 ml/min), less major bleeding was noted with apixaban than with warfarin (3.2% vs 6.4%). This study is the first of its kind, to our knowledge, to clinically evaluate the safety of apixaban compared with warfarin in a group of patients with severe renal dysfunction, including patients receiving dialysis. To our knowledge, no other factor Xa inhibitors have been clinically examined in this patient population. Based on the results of this study, apixaban seems to be a reasonable alternative to warfarin in patients with severe renal dysfunction who prefer a target-specific anticoagulant.
